Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study

Abstract

Background. Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design. Methods. We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study. Results. A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit. Conclusions. PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.

Preferences about Future Alzheimer’s Disease Treatments Elicited through an Online Survey Using the Threshold Technique

“…A downside of the use of thresholding is that it results in MAR values that are interval-censored, thereby complicating the statistical analysis. In previous applications of the threshold technique, interval-censored regression models with Gaussian errors have been used to handle the interval-censored data (48). Assuming a normal distribution for the population MAR values was, however, not appropriate for the preference information collected in our study.…”

Financing Biomedical Innovation

“…apply Bayesian patient-centered models to anti-infective therapeutics, incorporating epidemiological models to determine the optimal alpha during outbreaks of epidemic disease. Most recently, a survey of more than 2,700 Parkinson's disease (PD) patients by Hauber et al (2021) finds that risk thresholds in a BDA framework for new neurostimulative devices in the treatment of PD increase markedly with the perceived benefit of the device to the patient (see also Chaudhuri et al 2022). BDA has also been applied retrospectively to medical devices for treating obesity (Chaudhuri et al 2018) and to APTs (Chaudhuri & Lo 2021a), and it is being considered as a prospective input to the trial design of devices to treat kidney disease (Chaudhuri & Lo 2021b).…”

Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action

“…Co-authors ACD and MS are both people living with Parkinson’s disease, who have served as experts in a project that aimed at incorporating patient preferences into the design and evaluation of a clinical trial [ 17 ]. The aim of the project was to develop a tool to collect patient preference data, to be used in the evaluation of medical devices.…”